Sumanirol

Sumanirol
IUPAC ime
	(R)-5,6-dihidro-5-(metilamino)-4H-imidazo[4,5,1-ij]hinolin-2(1H)-on
Identifikatori
CAS broj	179386-43-7 ; 179386-44-8 (maleat)
ATC kod	none
PubChem	CID 9818479
ChemSpider	7994229
UNII	3E93IV1U45
Hemijski podaci
Formula	C11H13N3O
Molarna masa	203,240 g/mol
	SMILES CNC3Cn1c2c(C3)cccc2nc1=O; ;

Sumanirol (PNU-95,666) je visoko selektivni pun agonist D₂ receptora. On je prvi otkriveni agonist iz te grupe.^[1]^[2]^[3]

Sumanirol je razvijen za lečenje Parkinsonove bolesti i sindroma nemirnih nogu. Mada on nije odobren za kliničku upotrebu,^[4]^[5] on je korisno oruđe za bazna istraživanja neurobioloških mehanizama koji su bazirani na modu dejstva dopaminskog D2 receptora (vs. D1, D3, D4, i D5 receptora).^[3]

Reference

^ Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy. Journal of Organic Chemistry. 1997; 62(19):6582.
^ McCall RB, Lookingland KJ, Bédard PJ, Huff RM (2005). „Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1248—56. PMID 15980060. doi:10.1124/jpet.105.084202.
^ ^а ^б Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR (2010). „The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20 (6): 421—425. PMC 2864324  . PMID 20346635. doi:10.1016/j.euroneuro.2010.02.011.
^ Barone P, Lamb J, Ellis A, Clarke Z (2007). „Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease”. Movement Disorders : Official Journal of the Movement Disorder Society. 22 (4): 483—9. PMID 17115380. doi:10.1002/mds.21191.
^ Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (2007). „Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study”. Sleep Medicine. 8 (2): 119—27. PMID 17239657. doi:10.1016/j.sleep.2006.05.018.

Spoljašnje veze

[1] Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy. Journal of Organic Chemistry. 1997; 62(19):6582.

[pmid15980060-2] McCall RB, Lookingland KJ, Bédard PJ, Huff RM (2005). „Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1248—56. PMID 15980060. doi:10.1124/jpet.105.084202.

[pmid20346635-3] а ^б Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR (2010). „The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20 (6): 421—425. PMC 2864324  . PMID 20346635. doi:10.1016/j.euroneuro.2010.02.011.

[pmid17115380-4] Barone P, Lamb J, Ellis A, Clarke Z (2007). „Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease”. Movement Disorders : Official Journal of the Movement Disorder Society. 22 (4): 483—9. PMID 17115380. doi:10.1002/mds.21191.

[pmid17239657-5] Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (2007). „Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study”. Sleep Medicine. 8 (2): 119—27. PMID 17239657. doi:10.1016/j.sleep.2006.05.018.

[1]

[2]

[3]

[4]

[5]